text_1: Diabetic patients with acute coronary syndrome experience increased short-term and long-term risk for bleeding events.
text_2: METHODS AND RESULTS We performed a meta-analysis of the diabetic populations enrolled in the 6 large-scale platelet GP IIb/IIIa inhibitor ACS trials: PRISM, PRISM-PLUS, PARAGON A, PARAGON B, PURSUIT, and GUSTO IV.